At the heart of our success lies our highly competitive platform technology that is easily applicable across a wide range of infectious diseases: Themis' proprietary Themaxyn® platform.
The platform offers an innovative technology basis with a proven track record in safety and efficient manufacturing of vaccines with high potency. The scientific basis for Themis' measles vector Themaxyn® platform has been developed at the world renowned Institut Pasteur in Paris and is now licensed to Themis. It uses a well-established measles vaccine as a vaccination vector and large recombinant genes coding for selected antigens can been inserted into its genome. The Themaxyn® based vaccine delivers the selected antigens directly to macrophages and dendritic cells - the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to the selected antigens. As a replicating vector, the vaccine continuously expresses antigens even after immunization. This results in a powerful, antigen-focused immune response, which is expected to confer long-term immunity as does the measles vaccine.
- Standard measles vaccine used as vector backbone
- Large recombinant protein antigens are inserted
- Replicating vector expressing antigens after immunization
- Relevant surface and non-structural proteins expressed